Fosun Pharma's Subsidiary Henlius Enters into Licensing Agreement with Eisai for Serplulimab Injection in Japan

Source: Securities Times

People's Finance News, February 5thFosun Pharmaceutical(600196) On February 5, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its controlled subsidiary, Shanghai Henlius Biotech, Inc., entered into a "License Agreement" with Eisai Co., Ltd. Under the agreement, Eisai is granted rights to develop, manufacture, and commercialize Serplulimab Injection within the licensed territory (Japan) and field (oncology indications). According to the terms, Eisai shall pay Shanghai Henlius Biotech, Inc. up to US$155 million in non-refundable upfront and regulatory milestone payments. Additionally, based on the annual net sales of the licensed product within the licensed territory, Eisai shall make sales milestone payments to Shanghai Henlius Biotech, Inc. of up to US$233 million.

Fosun Pharmaceutical announced on the same day that the drug marketing application for Fumaning® (generic name: Rufolmetinib Tablets), independently developed by its holding subsidiary Fosun Pharmaceutical Industry for the treatment of adult patients with Type 1 Neurofibromatosis (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN), has been accepted by the National Medical Products Administration (NMPA) and included in the priority review process. The drug registration application for Cyclophosphamide Injection from its holding subsidiary Fresenius Kabi AG (Wuhan) has also been accepted by the NMPA.